GLI1 and neoplasm: We speculate that during treatment, there is a drop in levels of GLI1, as an end product of the Hh pathway, unless the tumour successfully maintains excessive activity of the Hh pathway via bypass pathways or adjunctive mutations that the treatment cannot overcome.